Not a Time for a Chill Pill
Steve Levy ⬥ September 9 While some companies can pursue UDRPs more sparingly, pharmaceutical companies generally have to be more aggressive in reclaim efforts. After all, even if a domain name does not receive much traffic, the potential harm associated with counterfeit drug sales or misleading information can be significant. Proof of bad faith, at […]
Not a Time for a Chill Pill Read More »